Bedrijfsvoering Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 17-01-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
246,27 ^USD	-1,16%		+3,48%	+4,66%

13/01	Alnylam Pharmaceuticals, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 09:45 AM
12/01	Alnylam Pharmaceuticals, Inc. Geeft winstrichtlijnen voor het hele jaar 2025	CI

Uitvoerend comité: Alnylam Pharmaceuticals, Inc.

Bedrijfsleider

Beklede functiesVan

Yvonne Greenstreet

62 jaar

Chief Executive Officer

01-01-2022

Timothy J. Maines

Chief Tech/Sci/R&D Officer

01-04-2023

Piyush Sharma

Compliance Officer

21-09-2022

Jeffrey Poulton

57 jaar

Director of Finance/CFO

13-08-2019

Kelley Boucher

Human Resources Officer

29-05-2019

Kevin Fitzgerald

57 jaar

Chief Tech/Sci/R&D Officer

01-09-2016

Pushkal Garg

57 jaar

Chief Tech/Sci/R&D Officer

29-10-2014

Christine Regan Lindenboom

44 jaar

Investor Relations Contact	01-09-2015
Public Communications Contact	01-09-2015

James Bilotta

Chief Tech/Sci/R&D Officer

01-10-2015

Alan Eisenberg

General Counsel

09-05-2017

Robert Hesslein

72 jaar

General Counsel	01-09-2024
Corporate Secretary	01-09-2024

Samenstelling van de raad van bestuur: Alnylam Pharmaceuticals, Inc.

Directeur

RadenVan

Amy Schulman

64 jaar

Governance Committee	01-09-2018
Nominating Committee	01-09-2018
Compensation Committee	01-07-2015
Audit Committee	25-01-2021
Compensation Committee Chair	25-01-2021

David Pyott

71 jaar

Executive Committee	07-04-2011
Governance Committee Chair
Nominating Committee Chair
Compensation Committee
Governance Committee	04-01-2016
Nominating Committee	04-01-2016
Audit Committee

Colleen Reitan

65 jaar

Audit Committee	25-09-2019
Compensation Committee Chair
HR Committee Chair
Compensation Committee	26-08-2019
Finance Committee	25-09-2019
Governance Committee Chair	25-09-2019
Nominating Committee Chair	25-09-2019

Dennis Ausiello

79 jaar

Governance Committee	26-04-2021
Nominating Committee	30-12-2021
Audit Committee	30-12-2021
Finance Committee	30-12-2021
Compensation Committee	30-12-2021

Charles Sigal

73 jaar

Governance Committee	08-06-2020
Nominating Committee	08-06-2020
Compensation Committee
HR Committee

Carolyn Bertozzi

58 jaar

Governance Committee	05-01-2023
Nominating Committee	05-01-2023
Compensation Committee

Olivier Brandicourt

68 jaar

Audit Committee	22-01-2024
Compensation Committee	02-03-2020
HR Committee	02-03-2020

Margaret Hamburg

69 jaar

Governance Committee	10-01-2019
Nominating Committee	10-01-2019

Peter Kellogg

67 jaar

Audit Committee	12-05-2021
Audit Committee Chair	29-09-2023

Phillip Sharp

80 jaar

Executive Committee
Compensation Committee	01-01-2017

Michael Bonney

66 jaar

Director/Board Member

05-01-2023

Yvonne Greenstreet

62 jaar

Director/Board Member

28-10-2021

Recente benoemingen: Alnylam Pharmaceuticals, Inc.

TransMedics benoemt Gerardo Hernandez als CFO; Aandelen dalen	03/12	MT
TransMedics benoemt Gerardo Hernandez als CFO; actualiseert de richtlijnen voor het volledige jaar 2024	02/12	MT
KalVista Pharmaceuticals, Inc. Benoemt Laurence Reid tot lid van de Raad van Bestuur	26/11	CI
Lexeo Therapeutics, Inc. benoemt Tolga Tanguler tot lid van de Raad van Bestuur	13/11	CI
Cognizant geselecteerd als IT-dienstverlener voor Alnylam	29-10-24	MT
Alnylam Pharmaceuticals, Inc. kondigt de overgang aan van Indrani L. Franchini als Executive Vice President, Chief Legal Officer en Secretary, met ingang van 1 maart 2024	19-01-24	CI
Marsha H. Fanucci neemt ontslag uit de Raad van Bestuur van Alnylam Pharmaceuticals, Inc.	28-09-23	CI

Meer nieuws

Voormalige zaakvoerders en bestuurders: Alnylam Pharmaceuticals, Inc.

Insider

Beklede functies

VanTot

Marsha Fanucci

Director/Board Member	08-12-2010	29-09-2023
Independent Dir/Board Member	08-12-2010	29-09-2023

Al Boyle

Chief Tech/Sci/R&D Officer

01-12-2015

01-04-2023

Masako Nakamura

Corporate Officer/Principal

20-06-2018

31-12-2022

Steven Paul

Director/Board Member	22-09-2010	16-04-2022
Independent Dir/Board Member	22-09-2010	16-04-2022

John Maraganore

Director/Board Member	01-12-2002	31-12-2021
Chief Executive Officer	01-12-2002	31-12-2021
Founder	01-12-2002	31-12-2021
President	01-12-2002	01-12-2007

Laurie Keating

General Counsel	17-09-2014	10-09-2021
Corporate Secretary	17-09-2014	10-09-2021

Jeff Miller

Corporate Officer/Principal

01-01-2016

01-03-2021

Barry Greene

Chief Operating Officer	01-10-2003	19-09-2016
President	01-10-2003	30-09-2020

Jing Marantz

Corporate Officer/Principal

20-06-2018

01-09-2020

Jae Kim

Corporate Officer/Principal

01-01-2016

01-07-2020

Paul Schimmel

Director/Board Member	14-06-2002	06-05-2020
Founder	14-06-2002	06-05-2020
Independent Dir/Board Member	14-06-2002	06-05-2020

Theresa Heggie

Corporate Officer/Principal

09-05-2017

01-05-2020

Nereyda Garcia

Compliance Officer

01-01-2016

01-12-2019

Manmeet Singh Soni

Comptroller/Controller/Auditor	09-10-2018	12-08-2019
Director of Finance/CFO	09-05-2017	12-08-2019

Mike Mason

Comptroller/Controller/Auditor	01-12-2005	01-10-2018
Director of Finance/CFO	02-12-2005	01-06-2016
Treasurer	01-02-2011	01-02-2019

John Clarke

Director/Board Member	14-06-2002	10-01-2019
Chairman	14-06-2002	01-01-2016
Founder	14-06-2002	10-01-2019
Independent Dir/Board Member	14-06-2002	10-01-2019

Karen Anderson

Human Resources Officer

17-09-2014

01-01-2019

Kevin Starr

Director/Board Member	01-09-2003	01-03-2018
Independent Dir/Board Member	01-09-2003	01-03-2018

Laura Sepp-Lorenzino

Corporate Officer/Principal

01-01-2014

01-09-2017

Peter F. Smith

Corporate Officer/Principal

09-05-2017

David-Alexandre Gros

Director of Finance/CFO	01-07-2016	06-01-2017
Corporate Officer/Principal	08-06-2015	01-07-2016

Mark Baglin

Sales & Marketing

01-01-2017

Benny Sorensen

Chief Tech/Sci/R&D Officer

01-07-2015

01-10-2016

Susanna High

Director/Board Member	01-02-2007	01-06-2008
Corporate Officer/Principal	01-06-2008	01-09-2016

Emmanuel Dulac

Corporate Officer/Principal

19-08-2016

Oved Amitay

Corporate Officer/Principal

27-06-2012

01-06-2016

Arianna Greco

General Counsel	01-01-2016	-
Corporate Officer/Principal	01-01-2016	-

Laurence Reid

Corporate Officer/Principal

04-06-2010

31-12-2014

Marko Kinchen Kozul

Corporate Officer/Principal

17-09-2014

Victor J. Dzau

Director/Board Member	01-04-2007	30-06-2014
Independent Dir/Board Member	01-04-2007	30-06-2014

Varun Kumar

Corporate Officer/Principal

01-04-2011

01-02-2014

Pritesh Gandhi

Chief Tech/Sci/R&D Officer

01-01-2014

Aria Tavana

Corporate Officer/Principal

01-01-2013

Nessan Bermingham

Corporate Officer/Principal

30-04-2012

Dinah Sah

Chief Tech/Sci/R&D Officer	01-04-2005	01-01-2012
Private Equity Investor	01-01-2010	01-01-2012

Kenneth S. Koblan

Chief Tech/Sci/R&D Officer	20-12-2010	02-06-2011
Corporate Officer/Principal	04-06-2010	20-12-2010

Vicki Sato

Director/Board Member

01-12-2005

30-04-2011

Patricia Allen

Director of Finance/CFO	01-05-2004	27-09-2010
Treasurer	01-05-2004	28-02-2011

James L. Vincent

Director/Board Member

01-07-2005

22-09-2010

Garvin L. Warner

Corporate Officer/Principal

01-08-2010

Ed Scolnick

Director/Board Member

01-02-2008

01-02-2010

Antonin Rollet de Fougerolles

Chief Tech/Sci/R&D Officer

01-01-2003

01-01-2010

Jason Rhodes

Corporate Officer/Principal

01-07-2007

01-01-2010

John Schmidt

Chief Tech/Sci/R&D Officer

01-10-2008

30-09-2009

Peter J. Williams

Corporate Officer/Principal

01-01-2006

Nagesh Mahanthappa

Corporate Officer/Principal

01-08-2002

01-02-2007

Mary DeLena

Corporate Officer/Principal

01-01-2007

Eric W. Raichle

Human Resources Officer

01-01-2007

John Berriman

Director/Board Member

01-07-2003

07-12-2005

Cynthia Clayton

Investor Relations Contact

01-01-2005

Robert A. Millman

Corporate Officer/Principal

09-09-2004

Lubomir Nechev

Corporate Officer/Principal

01-01-2004

Thomas R. Ulich

Chief Tech/Sci/R&D Officer

01-01-2003

01-01-2004

Vincent J. Miles

Corporate Officer/Principal

01-07-2003

Rachel Meyers

Chief Tech/Sci/R&D Officer

01-04-2003

Victor E. Kotelianski

Corporate Officer/Principal

01-04-2003

David M. Konys

Corporate Officer/Principal

01-04-2003

Peter Barrett

Director/Board Member

01-07-2002

David Altreuter

Corporate Officer/Principal

Edward E. Harlow

Corporate Officer/Principal

David Neafus

Director of Finance/CFO

Jian Xin Chen

Corporate Officer/Principal

Eric Ruby

General Counsel

Christoph Westphal

Director/Board Member	-	-
Founder	-	-

Akin Akinc

Corporate Officer/Principal

Jeffrey Behrens

Corporate Officer/Principal

Kathryn Morris

Public Communications Contact

Roy R. Lobb

Corporate Officer/Principal

Ulrich Bodner

Corporate Officer/Principal

Philip T. Chase

General Counsel

Jürgen Soutschek

Chief Tech/Sci/R&D Officer

Donna T. Ward

Corporate Officer/Principal

Stuart Pollard

Corporate Officer/Principal

Zachary A. Zimmerman

Corporate Officer/Principal

Mary D. Trueblood

Comptroller/Controller/Auditor

Marika St Amand

Human Resources Officer

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	29
Vrouw	5

Waarvan leden van het uitvoerend comité

Man	9
Vrouw	2

Waarvan bestuurders

Man	10
Vrouw	2

ESG MSCI

ESG

Milieu

Sociaal

Bedrijfsvoering

Controverse

Alnylam Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf. Het bedrijf houdt zich bezig met het ontdekken, ontwikkelen, produceren en commercialiseren van nieuwe therapeutica gebaseerd op ribonucleïnezuurinterferentie (RNAi). De producten die het bedrijf op de markt brengt zijn AMVUTTRA (vutrisiran) voor de behandeling van erfelijke transthyretine-gemedieerde amyloïdose (hATTR) met polyneuropathie bij volwassenen; ONPATTRO (patisiran) voor de behandeling van de polyneuropathie van hATTR amyloïdose bij volwassenen; GIVLAARI (givosiran) voor de behandeling van volwassenen met acute hepatische porfyrie; OXLUMO (lumasiran) voor de behandeling van primaire hyperoxalurie type 1, en Leqvio (inclisiran), dat ontwikkeld en gecommercialiseerd wordt door haar partner, Novartis AG, voor de behandeling van volwassenen met hypercholesterolemie of gemengde dyslipidemie. Daarnaast ontwikkelt het bedrijf Cemdisiran voor de behandeling van complement-gemedieerde ziekten, Belcesiran voor de behandeling van alfa-1 leverziekte, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran en andere.

Werknemers

2.100

Sector

Farmaceutische producten

Agenda

06-02-2025 - Q4 2024 Cijferpublicaties (schatting)

Meer informatie over het bedrijf